About Careers MedBlog Contact us

Tocilizumab For Giant Cell Arteritis Receives FDA Break Through Therapy Designation

by Madhumathi Palaniappan on October 6, 2016 at 10:47 AM
Font : A-A+

Tocilizumab For Giant Cell Arteritis Receives FDA Break Through Therapy Designation

The United States Food and Drug Administration has granted Break Through Therapy Designation for Roche's Tocilizumab (Actemra) drug for the treatment of Giant Cell Arteritis.

Giant Cell Arteritis is a chronic autoimmune condition caused by inflammation of arteries in the head and the aorta. The condition usually affects people above the age of 50 years. The disease may cause severe headaches, visual problems and jaw pain and is more likely to affect women when compared to men.


Tocilizumab from Roche has received prior approval in 2010 and the company continues to research and find new uses for the treatment of autoimmune diseases.

Break Through Therapy Designation from FDA is given for the treatment of life threatening diseases or symptoms. It is usually adopted as a part of FDA Safety and Innovation Act (FDASIA). This designation is given for the development of new drug which has preliminary clinical evidence demonstrating substantial improvement on atleast one existing therapy. Tocilizumab is the fifth best selling medicine of Roche which is prescribed for the treatment for rheumatoid and juvenile idiopathic arthritis. Sandra Horning, Chief Medical Officer said "The FDA Breakthrough Therapy designation for giant cell arteritis underscores our continued commitment to explore Actemra/RoActemra in autoimmune diseases with significant unmet need"

She also added that this drug would be the first new treatment for the condition in 50 years.

The company also said that Tocilizumab combined with six month steroid therapy were found to be more effective through the year compared to the standard 6 or 12 month steroid therapy.

Source: Medindia


Recommended Reading

Latest Drug News

 Understanding Why Aspirin is a Magic Drug for Inflammation
New discoveries about aspirin's interplay between messenger molecules that are crucial in the inflammatory proves again that it is a powerful anti-inflammatory drug.
Is Fomepizole the Key to Overcoming Antibiotic-Resistant Pneumonia?
The new drug target sheds insights into strategies to fight drug-resistant S. pneumoniae, stated research.
 Combination Therapy Benefits Septic Shock Patients
The effectiveness of adding fludrocortisone to hydrocortisone vs hydrocortisone alone among patients with septic shock was analyzed using target trial emulation.
Are Painkillers Safe for Back Pain?
Safety and effectiveness of commonly used painkillers (analgesics) for short-term relief of low back pain remain uncertain.
 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Tocilizumab For Giant Cell Arteritis Receives FDA Break Through Therapy Designation Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests